RafaelFonsecaMD
Hematology • Scottsdale, AZGetz Family Professor of Cancer, Professor of Medicine, Mayo Medical School Distinguished Mayo Investigator
Dr. Fonseca is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1994 - 1998
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1991 - 1994
Universidad Anahuac School of MedicineClass of 1991
Certifications & Licensure
AZ State Medical License 2004 - 2026
MN State Medical License 1994 - 2004- American Board of Internal Medicine Hematology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Clinical Trials
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Start of enrollment: 2004 Nov 03
- Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone Start of enrollment: 2007 Sep 01
- Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14).Hongwei Tang, Huihuang Yan, Suganti Shivaram, Stacey Lehman, Neeraj Sharma
Leukemia. 2024-10-14 - 1 citationsStill high risk? A review of translocation t(14;16) in multiple myeloma.Hira Mian, Martin Kaiser, Rafael Fonseca
American Journal of Hematology. 2024-10-01 - Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies.Kevin Guanwen Shim, Rafael Fonseca
Cancers. 2024-09-27
Journal Articles
- Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Abstracts/Posters
- Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to LenalidomideRafael Fonseca, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Current Obstacles in Myeloma Management: Debating the Evidence61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenstrom Macroglobulinemia, and Amyloidosis60th American Society of Hematology Annual Meeting - 11/30/2018
- Join now to see all
Press Mentions
7 Advances in CAR-T Cell Therapy at Mayo ClinicSeptember 19th, 2024- New Innovations Improve Cancer CareFebruary 3rd, 2023
- ISHOF CEO Brent Rutemiller Continues to Battle Leukemia; Will Work with Mayo ClinicAugust 17th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
